Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

585 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Short communication: Comparable safety and efficacy with once-daily versus twice-daily dosing of lopinavir/ritonavir tablets with emtricitabine + tenofovir DF in antiretroviral-naïve, HIV type 1-infected subjects: 96 week final results of the randomized trial M05-730.
González-García J, Cohen D, Johnson M, Sloan L, Fredrick L, Naylor C, da Silva B, Bernstein B; M05-730 Study Group. González-García J, et al. Among authors: naylor c. AIDS Res Hum Retroviruses. 2010 Aug;26(8):841-5. doi: 10.1089/aid.2009.0307. AIDS Res Hum Retroviruses. 2010. PMID: 20672994 Clinical Trial.
A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks.
Gathe J, da Silva BA, Cohen DE, Loutfy MR, Podzamczer D, Rubio R, Gibbs S, Marsh T, Naylor C, Fredrick L, Bernstein B. Gathe J, et al. Among authors: naylor c. J Acquir Immune Defic Syndr. 2009 Apr 15;50(5):474-81. doi: 10.1097/QAI.0b013e31819c2937. J Acquir Immune Defic Syndr. 2009. PMID: 19225400 Clinical Trial.
Post-kala-azar dermal leishmaniasis (PKDL) drug efficacy study landscape: A systematic scoping review of clinical trials and observational studies to assess the feasibility of establishing an individual participant-level data (IPD) platform.
Singh-Phulgenda S, Kumar R, Dahal P, Munir A, Rashan S, Chhajed R, Naylor C, Maguire BJ, Siddiqui NA, Harriss E, Rahi M, Alves F, Sundar S, Stepniewska K, Musa A, Guerin PJ, Pandey K. Singh-Phulgenda S, et al. Among authors: naylor c. PLoS Negl Trop Dis. 2024 Apr 16;18(4):e0011635. doi: 10.1371/journal.pntd.0011635. eCollection 2024 Apr. PLoS Negl Trop Dis. 2024. PMID: 38626228 Free PMC article.
Estimating the proportion of relapse following treatment of Visceral Leishmaniasis: meta-analysis using Infectious Diseases Data Observatory (IDDO) systematic review.
Chhajed R, Dahal P, Singh-Phulgenda S, Brack M, Naylor C, Sundar S, Alves F, Stepniewska K, Guerin PJ. Chhajed R, et al. Among authors: naylor c. Lancet Reg Health Southeast Asia. 2023 Dec 6;22:100317. doi: 10.1016/j.lansea.2023.100317. eCollection 2024 Mar. Lancet Reg Health Southeast Asia. 2023. PMID: 38482151 Free PMC article.
Haematological dynamics following treatment of visceral leishmaniasis: a protocol for systematic review and individual participant data (IPD) meta-analysis.
Munir A, Dahal P, Kumar R, Singh-Phulgenda S, Siddiqui NA, Naylor C, Wilson J, Buck G, Rahi M, Alves F, Malaviya P, Sundar S, Ritmeijer K, Stepniewska K, Pandey K, Guérin PJ, Musa A. Munir A, et al. Among authors: naylor c. BMJ Open. 2023 Dec 14;13(12):e074841. doi: 10.1136/bmjopen-2023-074841. BMJ Open. 2023. PMID: 38101841 Free PMC article.
585 results